AstraZeneca Announces Truqap Combination Approved In The U.S. As First And Only Targeted Treatment For PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

Benzinga Newsdesk www.benzinga.com Neutral 88.3%

Neg 0% Neu 88.3% Pos 0%

https://www.astrazeneca.com/media-centre/press-releases/2026/truqap-approved-in-us-for-prostate-cancer.html

Comments

No comments yet. Be the first!